Back to search
FDAFDA · Food and drugs·Recall number D-0838-2026

Revcovi (elapegademase-lvlr) Injection, 2.4mg/1.5mL (1.6 mg/mL), Single-Dose Vial, Rx Only, For Intramuscular Use Only, Mfd. by Chiesi USA, Inc., Cary, NC 27518, NDC 10122-502-01

Published September 9, 2026 · Recall initiated: August 19, 2026

Summary

FDA records drug Class III recall D-0838-2026, published September 9, 2026 and initiated August 19, 2026. Recalling firm: Chiesi USA, Inc.; Status: Ongoing; Reported quantity: 3,002 vials; Lot: Lot#: 1221973, Exp 3/24/2027. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Stability Specifications: Out of specification stability result for the protein concentration profile.

What to do

Voluntary: Firm initiated · Letter

Get an email if REVCOVI has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
REVCOVI
Manufacturer
Chiesi USA, Inc.
Distributor
MO, TN
Lot
Lot#: 1221973, Exp 3/24/2027
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Revcovi (elapegademase-lvlr) Injection, 2.4mg/1.5mL (1.6 mg/mL), Single-Dose Vial, Rx Only, For Intramuscular Use Only, Mfd. by Chiesi USA, Inc., Cary, NC 27518, NDC 10122-502-01 recalled?

Yes. FDA published recall D-0838-2026 on September 9, 2026. Reported hazard: Failed Stability Specifications: Out of specification stability result for the protein concentration profile.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: REVCOVI.